Clinical Trial

Study of XmAb942 in Healthy Participants and Participants With Ulcerative Colitis

Recruiting Phase 1/2
View on ClinicalTrials.gov →
Summary
The Phase 1 study described herein will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of XmAb942 in healthy volunteers (Parts A and B). Part C of this study will be a Phase 2 study to evaluate XmAb942 in participants with ulcerative colitis (UC).
Protocol Amendment History 4 changes
notable Trial sites expanded: 66 -> 90 locations 2026-07-25
notable Trial sites expanded: 57 -> 66 locations 2026-06-12
notable Trial sites expanded: 52 -> 57 locations 2026-05-07
notable Trial sites expanded: 40 -> 52 locations 2026-04-14
Trial Details
NCT Number NCT06619990
Lead Sponsor Xencor, Inc.
Conditions Ulcerative Colitis (UC)
Enrollment 270 participants
Start Date 2024-10-10
Primary Completion 2028-04 (estimated)
Study Completion 2029-01 (estimated)
Updated on ClinicalTrials.gov 2026-07-24